Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection

Abstract Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown tha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emiliano Chiarot, Eleonora Naimo, Alessia Corrado, Patrizia Giannetti, Immaculada Margarit Y. Ros, Giuliano Bensi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cd9e5cb5b5414982b11107dadfac8d4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd9e5cb5b5414982b11107dadfac8d4a
record_format	dspace
spelling	oai:doaj.org-article:cd9e5cb5b5414982b11107dadfac8d4a2021-11-08T10:53:56ZMaternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection10.1038/s41598-021-00941-z2045-2322https://doaj.org/article/cd9e5cb5b5414982b11107dadfac8d4a2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00941-zhttps://doaj.org/toc/2045-2322Abstract Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown that maternal vaccination with polysaccharide-based vaccines protects mothers and offspring from GBS mucosal colonization and consecutive infection. In these models, bacteria were inoculated in mouse either intravaginally in the last trimester of pregnancy or systemically in pups. Here, we investigated whether maternal vaccination with glycoconjugate vaccines may also prevent GBS-mediated colonization and disease in neonates using an infection route that more closely mimics inhalation or ingestion of bacteria during human delivery. To address this point, mice aged less than two days were intranasally challenged with epidemiologically relevant GBS strains. Bacteria were found to colonize nose and intestine, reaching in some cases lungs and blood during the first days of life. Bacteria were also found in vagina of a fraction of colonized female mice within the first month of life. GBS-specific IgG induced by maternal vaccination with a glycoconjugate vaccine formulation were found in blood and mucosal tissues of newborns. Finally, when intranasally challenged with GBS serotype III strains, pups delivered by vaccinated mothers were partially protected against mucosal colonization and deeper infection.Emiliano ChiarotEleonora NaimoAlessia CorradoPatrizia GiannettiImmaculada Margarit Y. RosGiuliano BensiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Emiliano Chiarot Eleonora Naimo Alessia Corrado Patrizia Giannetti Immaculada Margarit Y. Ros Giuliano Bensi Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
description	Abstract Group B Streptococcus (GBS) is generally an asymptomatic colonizer of human mucosa but it occasionally infects pregnant women and neonates through vertical transmission, causing disease during the first weeks of life with frequent and severe complications. Preclinical studies have shown that maternal vaccination with polysaccharide-based vaccines protects mothers and offspring from GBS mucosal colonization and consecutive infection. In these models, bacteria were inoculated in mouse either intravaginally in the last trimester of pregnancy or systemically in pups. Here, we investigated whether maternal vaccination with glycoconjugate vaccines may also prevent GBS-mediated colonization and disease in neonates using an infection route that more closely mimics inhalation or ingestion of bacteria during human delivery. To address this point, mice aged less than two days were intranasally challenged with epidemiologically relevant GBS strains. Bacteria were found to colonize nose and intestine, reaching in some cases lungs and blood during the first days of life. Bacteria were also found in vagina of a fraction of colonized female mice within the first month of life. GBS-specific IgG induced by maternal vaccination with a glycoconjugate vaccine formulation were found in blood and mucosal tissues of newborns. Finally, when intranasally challenged with GBS serotype III strains, pups delivered by vaccinated mothers were partially protected against mucosal colonization and deeper infection.
format	article
author	Emiliano Chiarot Eleonora Naimo Alessia Corrado Patrizia Giannetti Immaculada Margarit Y. Ros Giuliano Bensi
author_facet	Emiliano Chiarot Eleonora Naimo Alessia Corrado Patrizia Giannetti Immaculada Margarit Y. Ros Giuliano Bensi
author_sort	Emiliano Chiarot
title	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_short	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_full	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_fullStr	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_full_unstemmed	Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection
title_sort	maternal vaccination with a type-iii glycoconjugate protects mouse neonates against group b streptococcus intranasal infection
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cd9e5cb5b5414982b11107dadfac8d4a
work_keys_str_mv	AT emilianochiarot maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection AT eleonoranaimo maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection AT alessiacorrado maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection AT patriziagiannetti maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection AT immaculadamargarityros maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection AT giulianobensi maternalvaccinationwithatypeiiiglycoconjugateprotectsmouseneonatesagainstgroupbstreptococcusintranasalinfection
_version_	1718442568193146880

Maternal vaccination with a type-III glycoconjugate protects mouse neonates against Group B Streptococcus intranasal infection

Ejemplares similares